KOSDAQCosmetics241710

Cosmecca Korea

₩108,300▲ 10.06%2026-11-18 close
Market Cap
₩1.2T
Turnover
₩22.5B
Volume
210K
Shares out.
10.7M
PER
16.7×
PBR
3.5×
EPS
₩5,432
Dividend Yield
0.00%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q4–2026Q3) · Dividend yield is based on ₩0 per share · Prices as of the 2026-11-18 close

01

Report overview

Growth ahead of Ochang expansion; margin recovery is the test

Q3 2026 revenue rose 35.7% year on year, but operating profit grew only 0.1%, so the gap between top-line growth and profitability is the central issue for Cosmecca Korea.

  1. 1

    Revenue grew from KRW 399.4 billion in 2022 to KRW 640.9 billion in 2025, and operating margin rose from 2.6% to 13.0%.

  2. 2

    Operating margin in Q3 2026 was 11.0%, down from 14.9% a year earlier, as outsourcing expanded and the US subsidiary Englewood Lab weakened.

  3. 3

    In September 2026 the board approved KRW 136 billion of new facility investment at Ochang, which together with the plant bought in June makes a KRW 200 billion expansion.

  4. 4

    Borrowings rose from KRW 165.5 billion at end-2025 to KRW 225.8 billion at end-June 2026, and the debt ratio went from 87.9% to 119.6% over the same period.

  5. 5

    Samsung Securities, Shinyoung Securities and Yuanta Securities Korea kept Buy ratings or raised target prices in reports issued between September and November 2026.

02

Business structure

Cosmecca Korea is a cosmetics ODM and OEM specialist founded in 1999 that develops and manufactures products for domestic and overseas brands. It listed on KOSDAQ in 2016 and secured global production bases with the 2018 acquisition of Englewood Lab in the United States.

R&D staff account for 38% of total employees, and automated production and new formulation development are cited as the company's strengths. In Korea it ranks among the top three ODM players behind the Cosmax and Kolmar Korea duopoly.

By segment, the Korean business drives top-line growth: its Q3 2026 revenue was KRW 201.1 billion, up 54.9% year on year, with basic skincare making up 80.0% of that revenue. Englewood Lab reported Q3 2026 revenue of KRW 45.7 billion, equal to 18% of group revenue, but it fell 26.1% over the same quarter.

The Chinese subsidiary Cosmecca China posted Q3 2026 revenue of KRW 9.6 billion, up 17.9%, while recording an operating loss of KRW 1 billion.

Its customers are centered on K-beauty indie brands, and the company says initial order volumes from these brands have grown from tens of thousands of units to around one million. Annual production capacity is reported at about 1.3 billion units.

03

Earnings trend

Quarterly revenue · Operating profit
RevenueOperating profit
Annual revenue · Operating profit
RevenueOperating profit
Quarterly results · Last 5 quarters
QuarterRevenueOperating profitOp. margin
2025Q3₩182.4B₩27.2B14.9%
2025Q4₩178.5B₩21B11.8%
2026Q1₩185.1B₩21.9B11.8%
2026Q2₩226.1B₩32.1B14.2%
2026Q3₩247.5B₩27.2B11.0%
Annual results
YearRevenueOperating profitNet income (parent)Op. marginROEDebt-to-equity
2022₩399.4B₩10.4B₩2.7B2.6%1.8%89.7%
2023₩470.7B₩49.2B₩22.3B10.4%13.2%78.6%
2024₩524.3B₩60.4B₩42.8B11.5%19.6%68.4%
2025₩640.9B₩83.5B₩45.4B13.0%18.0%87.9%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-11-13

04

Earnings analysis

On the basis of filed annual results, revenue grew from KRW 399.4 billion in 2022 to KRW 470.7 billion in 2023 (up 17.9%), KRW 524.3 billion in 2024 (up 11.4%) and KRW 640.9 billion in 2025 (up 22.2%), rising three years in a row from 2023 through 2025.

Operating profit went from KRW 10.4 billion in 2022 to KRW 49.2 billion in 2023 (up 374.1%), KRW 60.4 billion in 2024 and KRW 83.5 billion in 2025 (up 38.4%). Operating margin climbed from 2.6% in 2022 to 10.4% in 2023, 11.5% in 2024 and 13.0% in 2025, with 2025 the largest year of the 2022 to 2025 period.

The company attributed 2025 results to growth across its Korean, US and Chinese subsidiaries and to a lower cost structure from production efficiency gains.

Profit attributable to owners of the parent was KRW 2.66 billion in 2022, KRW 22.3 billion in 2023, KRW 42.8 billion in 2024 and KRW 45.4 billion in 2025, and the 2025 rise of 6.2% sits far below the 38.4% operating profit growth.

Net income including non-controlling interests, a different figure, was KRW 57.8 billion in 2025. Operating cash flow fell from KRW 69.5 billion in 2024 to KRW 55 billion in 2025.

On a quarterly basis, Q4 2025 revenue of KRW 178.5 billion (down 2.1% from the prior quarter) was the low point, after which revenue was KRW 185.1 billion in Q1 2026, KRW 226.1 billion in Q2 and KRW 247.5 billion in Q3, rising for three consecutive quarters from Q1 to Q3 2026.

Q3 2026 operating profit of KRW 27.2 billion fell 15.1% from the prior quarter, and profit attributable to owners of KRW 10.9 billion fell 34.7% year on year.

Q3 operating margin of 11.0% compared with 14.9% a year earlier, which the company linked to a base effect from strong US results in 2025 and foreign currency translation losses from a weaker won. Profit attributable to owners over the latest four quarters (Q4 2025 to Q3 2026) totals KRW 58 billion.

05

Industry analysis

The cosmetics ODM market is being supported by strong K-beauty exports. Cumulative cosmetics exports reached USD 12.57 billion through October 2026, surpassing the full-year 2025 total of USD 11.42 billion in ten months.

The three leading domestic ODM companies are expected to produce more than 200 million cosmetic units a month, and all three are adding capacity. Cosmax is spending more than KRW 180 billion to expand its Pyeongtaek plant, while Kolmar Korea is preparing a Sejong plant expansion for July 2027.

Cosmecca Korea plans to invest KRW 200 billion in plant expansion through 2030. Industry commentary expects capacity shortages at all three companies to persist for some time.

Hana Securities estimated 2027 production capacity at 1.459 billion units for Cosmax, 1.015 billion for Kolmar Korea and 702 million for Cosmecca Korea.

In Q3 2026, Cosmax posted operating profit of KRW 83.3 billion (up 94.9% year on year) and Kolmar Korea KRW 81.9 billion (up 40.5%), while Cosmecca Korea's operating profit of KRW 27.2 billion was roughly flat year on year.

Industry analysis suggests Kolmar Korea and Cosmax secured new North American demand through color cosmetics, whereas Cosmecca Korea, with heavier reliance on basic skincare lines, was hit harder by weakness at its US subsidiary. The company is prioritizing top-line expansion and capacity, while its profitability metrics lag peers.

06

Outlook

The company's medium-term target is consolidated revenue of KRW 1 trillion in 2027. To that end it is investing KRW 200 billion in its Ochang plant in Cheongju, Chungcheongbuk-do, having bought a plant there for KRW 64 billion in June 2026 and approved KRW 136 billion of new facility investment in September 2026.

Construction started in September 2026, with production line installation set to begin in January 2027 and operations targeted for the second half of 2027. Full operation in 2028 and phased equipment additions through 2030 are included in the plan.

Reports differ on timing, with some listing the new plant's completion as July 2027. Samsung Securities views 2027 as a year where profitability recovery through lower outsourcing matters more than top-line growth.

Shinyoung Securities cited the Ochang expansion lines, which are to ramp in the second half of 2027, as the main growth driver. Englewood Lab's large customer reorder has been pushed to Q1 2027, which raises the possibility of weak results through Q4 2026.

Yuanta Securities Korea expects new product production at Englewood Lab to start in 2027. Samsung Securities pointed to Korean subsidiary order visibility in Q1 2027 and the pace of outsourced processing cost reduction as the points to watch.

07

Valuation

PER
16.7×
PBR
3.5×
ROE
22.6%
EPS
₩5,432
BPS
₩25,717
Dividend per share
₩0

Valuation is best read through the relationship between earnings recovery and the premium the share price carries. Profit attributable to owners was KRW 45.4 billion in 2025, while the latest four quarters total KRW 58 billion, above the full-year figure.

The direction of earnings recovery is clear, but quarter-to-quarter swings are large, so whether operating margin stabilizes is key to reading the multiples.

The price-to-book ratio sits at a wide premium to the KRW 252.7 billion of equity attributable to owners at end-2025, meaning the stock trades at a high multiple on an asset basis. Brokers have kept Buy ratings, citing capacity expansion and order recovery.

In a July 2026 report, Samsung Securities cited a rise in the ODM peer average multiple as a reason for raising its target price. Reading valuation starts with earnings capacity and the pace at which outsourcing is reduced, examined together.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-11-13

08

Bull factors

Korean business demand expansion

Korean business revenue in Q3 2026 reached KRW 201.1 billion, up 54.9% year on year, and passed KRW 200 billion in a quarter for the first time since the company was founded. Basic skincare sales rose 92.0% and accounted for 80.0% of Korean revenue. The company points to fast-rising orders from indie brands as the driver of demand.

KRW 1 trillion target for 2027 and capacity build-out

The company has set a target of KRW 1 trillion in consolidated revenue for 2027. The Ochang plant is targeted to begin operating in the second half of 2027, with full operation planned for 2028. Management says added capacity would reduce reliance on outsourcing and create room for margin recovery.

K-beauty export strength and Buy ratings from brokers

Cumulative cosmetics exports reached USD 12.57 billion through October 2026, passing full-year 2025 exports in ten months. Samsung Securities maintained its Buy rating and KRW 130,000 target price in a November 9, 2026 report.

Shinyoung Securities said in a November 9, 2026 report that it had raised its target price from KRW 125,000 to KRW 135,000.

09

Bear factors

Operating margin decline

Q3 2026 operating profit of KRW 27.2 billion rose only 0.1% year on year, and operating margin fell to 11.0% from 14.9%. Press reports said the result fell short of market expectations of about KRW 31.2 billion. Gross margin at the Korean business dropped 1.7 percentage points from the prior quarter to 19.7%.

Rising outsourcing costs

Combined outsourced processing and outsourcing costs rose from about KRW 46.6 billion in 2024 to about KRW 69 billion in 2025, up 48%, outpacing the 22% revenue growth over the same period.

Samsung Securities flagged the expansion of outsourced filling and packaging to meet short-lead-time orders as a profitability burden. A KRW 2.08 billion first-half bonus was booked as a one-off cost.

US subsidiary decline and higher borrowings

Englewood Lab's Q3 2026 revenue fell 26.1% to KRW 45.7 billion, and its operating profit dropped 61.0% to KRW 5.2 billion. Borrowings increased, and the debt ratio at end-June 2026 was higher than at end-2025, which adds to the financial burden. Operating cash flow also declined to KRW 55 billion in 2025 from KRW 69.5 billion in 2024.

10

Risk factors

Customer and portfolio concentration

Englewood Lab's portfolio is skewed toward basic skincare lines, which together with functional and OTC products made up about 90% of its Q3 2026 mix. Analysts note that a large customer's reorder has been pushed into Q1 2027. Timing of orders from a few clients can move quarterly results materially.

Expansion execution and funding

The KRW 200 billion expansion is scheduled for line installation in January 2027 and operation in the second half of 2027, though some reports give a July 2027 completion. With borrowings at KRW 225.8 billion at end-June 2026, construction delays or cost overruns could add financial strain. Any slip in start-up would also delay the reduction in outsourcing.

Currency and overseas subsidiary volatility

The company attributed the sharp drop in Q3 2026 net income to foreign currency translation losses from a weaker won. The Chinese subsidiary Cosmecca China recorded an operating loss of KRW 1 billion in Q3 2026, and in Q1 2026 part of its revenue slipped due to raw material supply delays. Currency swings and overseas subsidiary results can move consolidated earnings.

11

What to watch next

  1. January 2027

    Start of production line installation at the Ochang plant. Whether the second-half 2027 operating schedule holds is the check point.

  2. Q1 2027

    Visibility on new Korean business orders and the timing of the large Englewood Lab customer reorder, which bears on how much outsourced processing cost can be cut.

  3. Around mid-February 2027 (expected)

    Announcement of Q4 and full-year 2026 results. The timing is an estimate based on the prior year, when Q4 2025 results were released on February 20, 2026.

  4. End of March 2027

    Filing of the 2026 annual business report. Key items are the gap between operating margin gains and profit attributable to owners, along with outsourcing costs, borrowings and the debt ratio.

  5. Second half of 2027

    Operation of the Ochang plant, the path to full operation in 2028, and whether the KRW 1 trillion consolidated revenue target for 2027 is reached.

12

Overall view

Cosmecca Korea's revenue, operating profit and profit attributable to owners all rose from 2022 to 2025, and operating margin climbed from 2.6% to 13.0%. Q3 2026 revenue of KRW 247.5 billion, up 35.7%, shows the top-line momentum continuing.

Operating profit of KRW 27.2 billion rose only 0.1% in the same quarter, and operating margin fell to 11.0% from a year earlier. Higher outsourcing costs, weakness at the US subsidiary and currency translation losses are reported as the main causes of the margin squeeze.

On the balance sheet, borrowings and the debt ratio rose to mid-2026 levels. The company and brokers both describe margin recovery as contingent on the Ochang plant starting in the second half of 2027 and reducing outsourcing.

The points to confirm are Korean business order visibility and the Englewood Lab reorder timing in Q1 2027, along with full-year operating margin in the 2026 annual report.

Samsung Securities, Shinyoung Securities and Yuanta Securities Korea have kept Buy ratings or raised targets, while the factual risks above remain open.

13

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 18 more articles and sources
  1. etoday.co.kr
  2. fashionbiz.co.kr
  3. comp.wisereport.co.kr
  4. m.thebell.co.kr
  5. news1.kr
  6. news.nate.com
  7. m.news.nate.com
  8. ebn.co.kr
  9. m.news.nate.com
  10. thepublic.kr
  11. newsprime.co.kr
  12. newspim.com
  13. core.asiae.co.kr
  14. etoday.co.kr
  15. m.news.nate.com
  16. mt.co.kr
  17. investing.com
  18. news.nate.com

Report written 2026-11-14 · Data as of 2026-11-13

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis